First glimpse of controlled remdesivir data cast doubt on its COVID-19 treatment potential

After weeks of encouraging anecdotal and uncontrolled data for Gilead’s COVID-19 therapy remdesivir, the first hint of results from a placebo-controlled trial suggest that if the antiviral does provide a benefit, it may be closely correlated to treatment timing.

Data accidentally published to the World Health Organization’s website showed that a Phase III trial of remdesivir in patients with severe COVID-19 had a negative outcome. ...